First day of trading in Karolinska Development's portfolio company BioArctic's shares on Nasdaq Stockholm
(Thomson Reuters ONE) -
STOCKHOLM - 12 October, 2017. Karolinska Development's portfolio company
BioArctic Neuroscience AB was today listed on Nasdaq Stockholm. Karolinska
Development's holdings in BioArctic amounted to 3.17% prior to the listing.
Based on the issue price SEK 24 per B-share this corresponds to a value of SEK
48 million, approximately 80 times more than Karolinska Development's investment
in the company.
Karolinska Development announced in a press release on 13 September 2017
BioArctic's intention to list the company's B-shares. The trading in the
company's shares commenced today on Nasdaq Stockholm.
BioArctic is a research-intensive company that develops innovate biological
treatments with the potential to improve the quality of life for patients with
neurodegenerative diseases such as Alzheimer's and Parkinson's, moreover for
patients with severe spinal cord injuries.
"The value of Karolinska Development's ownership in BioArctic, at the time of
the listing, amounts to SEK 48 million and we are looking forward to closely
follow the company's continued development as a listed company on Nasdaq
Stockholm", says Viktor Drvota, CEO, Karolinska Development.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota(at)karolinskadevelopment.com
Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange(at)karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make a
difference to patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who are
leaders in their fields, supported by experienced management teams and advisers,
and co-funded by specialist international investors, to provide the greatest
chance of success.
Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a
proven track record as company builders and with access to a strong global
network.
For more information, please visit www.karolinskadevelopment.com
This information is information that Karolinska Development AB (publ) (Nasdaq
Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through the agency of
Viktor Drvota, at 08.00 CEST on 12 October 2017.
BioArctic first day of trading (ENG):
http://hugin.info/143071/R/2141304/820080.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.10.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 563403
Anzahl Zeichen: 3997
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"First day of trading in Karolinska Development's portfolio company BioArctic's shares on Nasdaq Stockholm"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
